383 related articles for article (PubMed ID: 28396547)
21. A Ceftazidime-Avibactam-Resistant and Carbapenem-Susceptible Klebsiella pneumoniae Strain Harboring
Niu S; Chavda KD; Wei J; Zou C; Marshall SH; Dhawan P; Wang D; Bonomo RA; Kreiswirth BN; Chen L
mSphere; 2020 Aug; 5(4):. PubMed ID: 32848008
[TBL] [Abstract][Full Text] [Related]
22. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment.
Gaibani P; Campoli C; Lewis RE; Volpe SL; Scaltriti E; Giannella M; Pongolini S; Berlingeri A; Cristini F; Bartoletti M; Tedeschi S; Ambretti S
J Antimicrob Chemother; 2018 Jun; 73(6):1525-1529. PubMed ID: 29566151
[TBL] [Abstract][Full Text] [Related]
23. Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based β-lactamase inhibitor combinations and cefiderocol.
Di Pilato V; Codda G; Niccolai C; Willison E; Wong JLC; Coppo E; Frankel G; Marchese A; Rossolini GM
Int J Antimicrob Agents; 2024 Jan; 63(1):107030. PubMed ID: 37931849
[TBL] [Abstract][Full Text] [Related]
24. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2.
Hemarajata P; Humphries RM
J Antimicrob Chemother; 2019 May; 74(5):1241-1243. PubMed ID: 30753572
[TBL] [Abstract][Full Text] [Related]
25. Patient-to-Patient Transmission of Klebsiella pneumoniae Carbapenemase Variants with Reduced Ceftazidime-Avibactam Susceptibility.
Munoz-Price LS; Reeme AE; Buchan BW; Mettus RT; Mustapha MM; Van Tyne D; Shields RK; Doi Y
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31332070
[TBL] [Abstract][Full Text] [Related]
26. Loss and gain of ceftazidime-avibactam susceptibility in a non-carbapenemase-producing K1-ST23 hypervirulent
Zhao J; Pu D; Li Z; Zhang Y; Liu X; Zhuo X; Lu B; Cao B
Virulence; 2024 Dec; 15(1):2348251. PubMed ID: 38697754
[TBL] [Abstract][Full Text] [Related]
27. First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
Humphries RM; Yang S; Hemarajata P; Ward KW; Hindler JA; Miller SA; Gregson A
Antimicrob Agents Chemother; 2015 Oct; 59(10):6605-7. PubMed ID: 26195508
[TBL] [Abstract][Full Text] [Related]
28. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
[TBL] [Abstract][Full Text] [Related]
29. The postantibiotic effect and post-β-lactamase-inhibitor effect of ceftazidime, ceftaroline and aztreonam in combination with avibactam against target Gram-negative bacteria.
Pillar CM; Stoneburner A; Shinabarger DL; Krause KM; Nichols WW
Lett Appl Microbiol; 2016 Aug; 63(2):96-102. PubMed ID: 27221329
[TBL] [Abstract][Full Text] [Related]
30. Effects of KPC Variant and Porin Genotype on the
Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
[TBL] [Abstract][Full Text] [Related]
31. Genomic characterization of an extensively drug-resistant KPC-2-producing Klebsiella pneumoniae ST855 (CC258) only susceptible to ceftazidime-avibactam isolated in Brazil.
Aires CAM; Rybak MJ; Yim J; Pereira PS; Rocha-de-Souza CM; Albano RM; Cavalcanti VO; D'Alincourt Carvalho-Assef AP; Gomes MZR; Asensi MD
Diagn Microbiol Infect Dis; 2017 Dec; 89(4):324-327. PubMed ID: 29021086
[TBL] [Abstract][Full Text] [Related]
32. Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D
Compain F; Arthur M
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461318
[TBL] [Abstract][Full Text] [Related]
33. Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.
Hobson CA; Pierrat G; Tenaillon O; Bonacorsi S; Bercot B; Jaouen E; Jacquier H; Birgy A
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0044722. PubMed ID: 35980232
[TBL] [Abstract][Full Text] [Related]
34.
Barnes MD; Winkler ML; Taracila MA; Page MG; Desarbre E; Kreiswirth BN; Shields RK; Nguyen MH; Clancy C; Spellberg B; Papp-Wallace KM; Bonomo RA
mBio; 2017 Oct; 8(5):. PubMed ID: 29089425
[TBL] [Abstract][Full Text] [Related]
35. Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate.
Both A; Büttner H; Huang J; Perbandt M; Belmar Campos C; Christner M; Maurer FP; Kluge S; König C; Aepfelbacher M; Wichmann D; Rohde H
J Antimicrob Chemother; 2017 Sep; 72(9):2483-2488. PubMed ID: 28637339
[TBL] [Abstract][Full Text] [Related]
36. Increased gene expression and copy number of mutated bla
Sun L; Li H; Wang Q; Liu Y; Cao B
BMC Microbiol; 2021 Aug; 21(1):230. PubMed ID: 34412588
[TBL] [Abstract][Full Text] [Related]
37. Mutations in porin LamB contribute to ceftazidime-avibactam resistance in KPC-producing Klebsiella
Guo Y; Liu N; Lin Z; Ba X; Zhuo C; Li F; Wang J; Li Y; Yao L; Liu B; Xiao S; Jiang Y; Zhuo C
Emerg Microbes Infect; 2021 Dec; 10(1):2042-2051. PubMed ID: 34551677
[TBL] [Abstract][Full Text] [Related]
38. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
Tsivkovski R; Lomovskaya O
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
[TBL] [Abstract][Full Text] [Related]
39. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in
Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067
[TBL] [Abstract][Full Text] [Related]
40. Isolation of a Ceftazidime-Avibactam-Resistant
Shen S; Shi Q; Han R; Guo Y; Yang Y; Wu S; Yin D; Hu F
Microbiol Spectr; 2022 Feb; 10(1):e0184021. PubMed ID: 35080422
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]